- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint alleged Forxiga ‘Prescribing & Dosing’ webpage omitted “critical” SPC warnings for moderate renal impairment (PTH increase, hypotension). Panel ruled no breach…
Complaint alleged repeated brand-name use and patient-record style questions in Abilify Maintena ATU tracking market research (2018–2021). PMCPA Panel found the activity…
A former creative agency posted about past work and referenced Emerade on social media. PMCPA ruled the agency was not a third…
Daiichi Sankyo’s Nustendi promotional website omitted a contraindication (with statin in active liver disease/persistent transaminase elevations) on the tolerability page. Panel found…
GSK’s GSK.pro page claimed Trelegy had greater exacerbation reduction vs “another” triple therapy without naming the comparator. Panel found the headline implied…
Calquence “How to dose” leaflet said no dose adjustment for moderate hepatic impairment but omitted SmPC caveat to closely monitor for toxicity.…
Roche promotional materials for Vabysmo (faricimab) were ruled misleading where “first and only” wording and “may confer additional benefits” implied special clinical…
PMCPA found Roche breached Clause 5.5 because a patient summary of an AMD audit report did not disclose Roche’s funding within the…
A third-party publisher sent an EU-focused Pluvicto promo email to UK HCPs after a “Europe” targeting error. Panel found disguised promotion, unclear…
A Jardiance case-study slide deck remained accessible via a live URL long after retirement, wasn’t recertified within 2 years, and the PI…
Jazz funded a patient organisation’s health information project, but Jazz’s involvement wasn’t clearly acknowledged from the outset on the website and wasn’t…
A UK health professional complained about Janssen’s HCP website. The Panel found some prescribing information was out-of-date, one graph exaggerated differences, and…
A GP complained that he continued to receive promotional emails after opting out. A third-party agency failed to remove his details, and…
A Financial Times article triggered a Director complaint about Lilly’s 40over40 ED campaign. TV ad was not in breach, but website/leaflet treatment…
AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading. The Panel found the chart acceptable in context and ruled no…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.